Journal of Isfahan Medical School

Journal of Isfahan Medical School

Comparison of CD105 Expression in Different Histological Grades of Oral Squamous Cell Carcinoma and Healthy Oral Mucosa by Immunohistochemistry

Document Type : Original Article(s)

Authors
1 Department of Dentistry, School of Dentistry, Isf.C., Islamic Azad University, Isfahan, Iran
2 Department of Oral & Maxillofacial Pathology, School of Dentistry, Isf.C., Islamic Azad University, Isfahan, Iran
10.48305/jims.v44.i874.1482
Abstract
Introduction: Oral squamous cell carcinoma (OSCC) is the most common malignancy of the oral cavity, and angiogenesis plays a critical role in its growth and progression. CD105 (endoglin) is a membrane protein recognized as a specific marker of neoangiogenesis and may have prognostic value in patients with OSCC. This study aimed to assess CD105 expression in OSCC and compare it with normal oral mucosa.
Materials and Methods: In this cross-sectional study, archival samples including 13 OSCC specimens with different grades of differentiation (well, moderate, poor) and 5 normal oral mucosa samples were examined. CD105 expression was evaluated using immunohistochemistry, and microvessel density was counted in hotspot areas. Data were analyzed using appropriate statistical tests, and a significance level of p < 0.05 was considered.
Results: CD105 expression was significantly higher in OSCC compared with normal mucosa (p = 0.000). The mean CD105 expression increased with decreasing tumor differentiation; the highest expression was observed in poorly differentiated tumors, while the lowest was in well-differentiated tumors (p = 0.043).
Conclusion: The elevated expression of CD105 in tumor tissues compared with normal mucosa and its association with lower differentiation indicate a key role of this marker in tumor neoangiogenesis and OSCC progression. Therefore, CD105 can be considered a valuable biomarker for predicting disease severity and a potential target for anti-angiogenic therapy.

Highlights

Nader Kalbasi: Google Scholar

Keywords
Subjects

1.     Badwelan M, Muaddi H, Ahmed A, Lee KT, Tran SD. Oral squamous cell carcinoma and concomitant primary tumors: What do we know? A review of the literature. Curr Oncol 2023; 30(4): 3721–34.
2.     Romano A, Di Stasio D, Petruzzi M, Fiori F, Lajolo C, Santarelli A, et al. Noninvasive imaging methods to improve the diagnosis of oral carcinoma and its precursors: State of the art and proposal of a three-step diagnostic process. Cancers (Basel) 2021; 13(12): 2864.
3.     Jokar M, Namavari N, Moshiri SA, Kargar Jahromi H, Rahmanian V. The incidence of oral cavity cancer in Iran: A systematic review and meta-analysis. Cancer Reports 2023; 6(6): e1836.
4.     Tan Y, Wang Z, Xu M, Li B, Huang Z, Qin S, et al. Oral squamous cell carcinomas: state of the field and emerging directions. Int J Oral Sci 2023; 15(1): 44.
5.     Kinane DF, Gabert J, Xynopoulos G, Guzeldemir‐Akcakanat E. Strategic approaches in oral squamous cell carcinoma diagnostics using liquid biopsy. Periodontol 2000 2024; 96(1): 316–28.
6.     Muralidharan S, Nikalje M, Subramaniam T, Koshy JA, Koshy AV, Bangera D. A narrative review on oral squamous cell carcinoma. J Pharm Bioallied Sci 2025; 17(Suppl 1): 59–66.
7.      Abati S, Bramati C, Bondi S, Lissoni A, Trimarchi M. Oral Cancer and Precancer: A Narrative Review on the Relevance of Early Diagnosis. International Journal of Environmental Research and Public Health 2020; 17(24): 9160.
8.      Dey S, Singh AK, Singh AK, Rawat K, Banerjee J, Agnihotri V, Upadhaya D. Critical pathways of oral squamous cell carcinoma: molecular biomarker and therapeutic intervention. Medical Oncology 2022; 39(3): 30.
9.     Mishra MK, Gupta S, Shivangi, Sharma M, Sehgal S. The repertoire of mutational signatures in tobacco- and non-tobacco-induced oral cancer. Clin Transl Oncol 2023; 25(12): 3332-49.
10.  Micaily I, Johnson J, Argiris A. An update on angiogenesis targeting in head and neck squamous cell carcinoma. Cancers Head Neck 2020; 5: 5.
11.  Ollauri-Ibáñez C, Ayuso-Íñigo B, Pericacho M. Hot and cold tumors: Is endoglin (CD105) a potential target for vessel normalization? Cancers 2021; 13(7): 1552.
12.  Tazat K, Pomeraniec-Abudy L, Hector-Greene M, Szilágyi SS, Sharma S, Cai EM, Corona AL, Ehrlich M, Blobe GC, Henis YI. ALK1 regulates the internalization of endoglin and the type III TGF-β receptor. Mol Biol Cell 2021; 32(7): 605-621.
13.  González Muñoz T, Amaral AT, Puerto-Camacho P, et al. Endoglin in the Spotlight to Treat Cancer. Int J Mol Sci 2021; 22(6): 3186.
14.  Li D, Zheng M, Zhang W, He J, Zhang L, Tan Q, Maghsoudloo M, Liu K, Li T, Yao R, Wei C, Cheng J, Fu J. Evaluation of ENG/CD105 expression, methylation, immuno-response, and cordycepin (CD) regulation as a novel biomarker of breast invasive carcinoma (BRCA). J Cancer 2024; 15(16): 5244-57.
15.  Liu Y, Paauwe M, Nixon AB, Hawinkels LJAC. Endoglin Targeting: Lessons Learned and Questions That Remain. Int J Mol Sci 2020; 22(1): 147.
16.  Li L, Zhong L, Tang C. CD105: tumor diagnosis, prognostic marker and future tumor therapeutic target Clin Transl Oncol 2022; 24(8): 1447-58.
17.  Roškar L, Roškar I, Rižner TL, Smrkolj Š. Diagnostic and Therapeutic Values of Angiogenic Factors in Endometrial Cancer. Biomolecules 2021; 12(1): 7. 
18.  Litwiniuk-Kosmala M, Makuszewska M, Czesak M. Endoglin in head and neck neoplasms. Front Med (Lausanne) 2023; 10: 1115212.
19.  Ramchandra Gadbail A, Korde S, Chaudhary MS, Sarode SC, Gondivkar SM, Dande R, et al. Ki67, CD105, and α-SMA Expression Supports Biological Distinctness of Oral Squamous Cell Carcinoma Arising in the Background of Oral Submucous Fibrosis. Asian Pac J Cancer Prev 2020; 21(7): 2067-74.
20.  Steigen SE, Søland TM, Nginamau ES, Laurvik H, Costea D, Johannessen AC, et al. Grading of oral squamous cell carcinomas, Intra- and interrater agreeability: Simpler is better? J Oral Pathol Med 2020; 49(7): 630–5.
21.  Gudipati ABK. An immunohistochemical assessment of endoglin (CD105) expression in oral epithelial dysplasias and oral squamous cell carcinomas. Am J Clin Case Rep 2023; 4: 1-6.
22.  Mahapatra N, Uma Rao KD, Ranganathan K, Joshua E, Thavarajah R. Study of expression of endoglin (CD105) in oral squamous cell carcinoma J Oral Maxillofac Pathol 2021; 25(3): 552.
23.  Derakhshan S, Mahdavi N, Kardouni Khoozestani N, Nasr Esfahani B, Heidarian F, Rahrotaban S, et al. Assessment of the association of OCT3/4 with GLUT1 and CD105 in oral squamous cell carcinoma using dual immunohistochemistry. BMC Oral Health 2022; 22(1): 300.
24.  Batistella EA, Fernanda Paza Miguel A, Lonni Nascimento N, Campolina Rebello Horta M, Serafin Couto Vieira D, Riet Correa Rivero E, et al. Microvascular density analysis and histological parameters of oral cancer progression. Oral Dis 2024; 30(4): 2110-21.
25.  Gadbail AR, Chaudhary M, Tekade SA, Hande A, Yuwanati M, Nimonkar  P, Gondivkar SM, et al. Prognostic Significance of CD105-Assessed Angiogenesis in Relation to Survival and Clinicopathological Features of Oral Squamous Cell Carcinoma. J Oral Pathol Med 2026; 55(7): 805-11.
26.  Ghafari R, Jalayer Naderi N, Emami Razavi A. A retrospective institutional study of histopathologic pattern of Oral Squamous Cell Carcinoma (OSCC) in Tehran, Iran during 2006-2015. J Res Med Sci 2019; 24: 53.
27.  Mahapatra N, Uma Rao KD, Ranganathan K, Joshua E, Thavarajah R. Study of expression of endoglin (CD105) in oral squamous cell carcinoma. J Oral Maxillofac Pathol 2021; 25(3): 552.
28.  Kumari KS, Kanth MR, Vidyadhari P, Vidya KS, Spandana G, Sowmya K, et al. Discerning the vascular transition in oral cancer: Comparative study of CD105 expression in normal, premalignant and malignant oral epithelium J Oral Maxillofac Pathol 2026; 30(1): 139-44.
29.  Basnaker M, Shashikanth SR, BNVS S. Expression of endoglin (CD-105) and microvessel density in oral dysplasia and squamous cell carcinoma. J Clin Diagn Res 2014; 8(9): ZC914.
Volume 44, Issue 874
1st Week, October
September and October 2026
Pages 1482-1488

  • Receive Date 10 August 2026
  • Accept Date 16 August 2026